4-methyloxazole-5-carbonitrile

Acute Toxicity: dermal

Administrative data

Endpoint:

acute toxicity: dermal

Type of information:

experimental study

Adequacy of study:

key study

Reliability:

1 (reliable without restriction)

Data source

Reference

Reference Type:

study report

Title:

Unnamed

Year:

2011

Report date:

2011

Materials and methods

Test guideline

Qualifier:

according to guideline

Guideline:

OECD Guideline 402 (Acute Dermal Toxicity)

Deviations:

no

GLP compliance:

yes (incl. QA statement)

Test type:

fixed dose procedure

Limit test:

yes

Test material

Test material information

Constituent 1

Reference substance name:

4-methyloxazole-5-carbonitrile

EC Number:

213-709-7

EC Name:

4-methyloxazole-5-carbonitrile

Cas Number:

1003-52-7

Molecular formula:

C5H4N2O

IUPAC Name:

4-methyl-1,3-oxazole-5-carbonitrile

Test animals

Species:

rat

Strain:

Wistar

Sex:

male/female

Administration / exposure

Type of coverage:

semiocclusive

Vehicle:

unchanged (no vehicle)

Duration of exposure:

24 h

Doses:

1.79 mL/kg

No. of animals per sex per dose:

4 per sex, only one dose

Control animals:

yes

Results and discussion

Effect levels

Sex:

male/female

Dose descriptor:

LD50

Effect level:

> 2 000 mg/kg bw

Based on:

test mat.

Any other information on results incl. tables

-

Applicant's summary and conclusion

Interpretation of results:

not classified

Remarks:

Migrated information Criteria used for interpretation of results: EU

Executive summary:

CMO was tested for acute dermal toxicity in compliance with GLP and in compliance with OECD 402 (1987) guideline. Five male and five female RccHan:WIST (SPF) rats were treated with CMO at 2000 mg/kg by dermal application. The test item was applied undiluted and administered at a volume dose of 1.79 mL/kg. The application period was 24 hours. The animals were examined daily during the acclimatization period and mortality, viability and clinical signs were recorded. All animals were examined for clinical signs before treatment, within the first 30 minutes and approximately 1, 2, 3 and 5 hours after treatment on test day 1 and once daily during test days 2-15. Local signs were noted once daily on test days 2-15. Mortality / viability was recorded before treatment, within the first 30 minutes and approximately 1, 2, 3 and 5 hours after administration on test day 1 (with the clinical signs) and twice daily on test days 2-15. Body weights were recorded on test day 1 (prior to administration) and on test days 8 and 15. All animals were necropsied and examined macroscopically.

No intercurrent deaths occurred during the Course of the study and no clinical signs were recorded throughout the entire observation period. Very slight erythema was observed in four of five males and four of five fernales afler rernoval of the test itern on test day 2. No local dermal signs were obsewed from test day 3 until the end of the observation period. The body weight of the animals was within the range cornrnonly recorded for anirnals of this strain and age. All animals gained weight during the experimental phase. No rnacroscopic findings were observed at necropsy. The median lethal dose (LD50) of CMO after single dermal administration to rats of both Sexes, observed over a period of 14 days, is greater than 2000 rng/kg body weight